To include your compound in the COVID-19 Resource Center, submit it here.

Plan B in HCV

After Inhibitex: BMS hopes it is back in running with triple oral combo in HCV

Bristol-Myers Squibb Co.'s HCV ambitions did not die with Inhibitex Inc.'s INX-189. The pharma believes its next choice for all-oral regimen involving NS3 protease, NS5A protein and non-nucleoside NS5B inhibitors has the safety and convenience to compete with more advanced rivals in HCV genotype 1 infection.

Last week, BMS said the triple combination achieved competitive SVR rates in a Phase IIa trial.

When INX-189 (BMS-986094) imploded last August, it seemed to leave a hole in BMS's HCV portfolio based on the conventional wisdom that a nucleoside NS5B polymerase inhibitor must be the backbone of an all-oral, interferon-free HCV regimen (see BioCentury, Sept. 10, 2012).

Moreover, the competition would be stretching out its lead.


Read the full 1104 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers